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Abstract
Background: Three-dimensional (3D) cell cultures and 3D bioprinting have recently gained attention based on
their multiple advantages over two-dimensional (2D) cell cultures, which have less translational potential to
recapitulate human physiology. 3D scaffold supports, cell aggregate systems and hydrogels have been shown
to accurately mimic native tissues and support more relevant cell-cell interactions for studying effects of drugs
and bioactive agents on cells in 3D. The development of cost-effective, high-throughput and scaffold-free microtissue
assays remains challenging. In the present study, consumer grade 3D printing was examined as a fabrication method
for creation of high-throughput scaffold-free 3D spheroidal microtissues.
Results: Consumer grade 3D printing was capable of forming 96-well cell culture inserts to create scaffold-free
microtissues in liquid suspensions. The inserts were seeded with human glioblastoma, placental-derived mesenchymal
stem cells, and intestinal smooth muscle cells. These inserts allowed for consistent formation of cell density-controllable
microtissues that permit screening of bioactive agents.
Conclusion: A variety of different cell types, co-cultures, and drugs may be evaluated with this 3D printed microtissue
insert. It is suggested that the microtissue inserts may benefit 3D cell culture researchers as an economical assay
solution with applications in pharmaceuticals, disease modeling, and tissue-engineering.
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Background
Three-dimensional (3D) printing, also known as additive
manufacturing, is expected to be a disruptive manu-
facturing technique and have applications in a variety
of future biomedical technologies. The technique in-
volves a bottom-up fabrication, where systems and
constructs are created in a layer-by-layer manner. 3D
printing has been used for decades and more recently
has experienced numerous advancements in speed,
resolution, accuracy, cost, and biocompatible materials.
Materials that are now compatible with 3D printing in-
clude; metals, ceramics, plastics, foods, electronics, bio-
polymers and living cells [1, 2].
Interest in medical applications of 3D printing is rap-
idly expanding. Customized surgical tools, guides, im-
plants, prosthetics, and preoperative planning have been
used successfully in patient treatment [3–5]. It is
thought that customized tissues and organs will also be
feasible in the future through 3D bioprinting. 3D bio-
printing allows for complex scaffold geometries to be
fabricated with desired cell types encapsulated within
biomaterials. While the field of 3D bioprinting is still in
its infancy, it is experiencing major market growth and
holds tremendous potential in tissue engineering,
pharmaceutical research, disease modeling, and drug
discovery [6].
3D cell cultures have recently gained tremendous at-
tention due to their superiority over 2D cell cultures,
which have less translational potential. Cell proliferation,
drug uptake, cell morphology, oxygenation, nutrient up-
take, waste excretion, and junction protein contents all
differ when comparing 3D to 2D cell culture [7]. 3D
scaffold supports, cell aggregate systems and hydrogels
have been shown to more accurately mimic native tis-
sues and support more relevant cell-cell interactions for
studying actions of drugs and bioactive agents [8–12].
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3D cell cultures can be fabricated through a variety of
techniques including; 3D bioprinting, low-attachment
culture plates, liquid suspension, microfluidics, and
magnetic levitation [13, 14]. Here, consumer grade 3D
printing was examined as a fabrication method for
creation of high-throughput scaffold-free 3D spheroidal
microtissues.
Methods
3D microtissue insert design and fabrication
Ninety-six well 3D-microtissue inserts were generated
using computer-aided design (CAD) software (Tinker-
CAD, AutoDesk, San Francisco, California). Upper
openings of the well inserts were designed with internal
tapering to guide pipet tips while the well bottoms were
designed with negative hemispherical spacing to hold
cell-laden droplets (see Figs. 1, 2). Ninety-six well inserts
were 3D printed using polylactic acid (PLA) (PLA-Pro,
eSun, Shenzhen, China) at 205 °C on a Lulzbot Taz-6 3D
printer (Lulzbot, Aleph Objects, Loveland, Colorado)
and were 3D printed in an inverted (180° - upside down)
configuration with supports off. Finished 3D printed in-
serts were removed from the print bed with a spatula
and the prints were briefly exposed to a heat gun (~
200 °C) to remove small flash fibers created during the
print process. Additionally, any unwanted larger print
defects were manually removed with surgical scissors.
Finished 3D printed inserts were submerged in 70%
ethanol for 24 h and allowed to air dry over-night in a
sterile cell culture hood before beginning cellular
experiments.
3D microtissue formation and analysis
Three different cell types were examined with the 3D
printed inserts. Human placental-derived mesenchymal
stem cells (h-PMSC), U87 MG human glioblastoma cells
(U87), and human intestinal smooth muscle cells
(h-ISMC) were all grown to confluency in flat polystyr-
ene flasks, trypsinized (0.2%/4 mM EDTA), and resus-
pended in Dulbecco’s Modified Eagle’s medium
(DMEM) containing 10% fetal bovine serum (FBS), 1%
penicillin/streptomycin (P/S), and 4.5 g glucose/liter (‘in-
sert media’). The 3D printed microtissue inserts were
placed in standard flat-bottom 96 well plates and were
seeded with 40 μl (μl) of insert media with cells sus-
pended in each drop. The solution pipetting rate was
performed slowly to allow droplets to form underneath
the 3D printed insert.
Cells seeded in 3D printed inserts were incubated at
37 °C, 7.5% carbon dioxide (CO2), and 100% humidity
for 72 h (hrs.). Cells were monitored in the 3D printed
inserts over the course of 72 h. while in liquid suspen-
sion. Cell-loaded 3D printed insert were monitored by
both optical and fluorescence microscopy on an EVOS
FL Cell Imaging System (ThermoFisher Scientific, Wal-
tham, Massachusetts). 3D spheroids were live-dead la-
beled with Calcein-AM, Ethidium Homodimer-1, and
Hoechst 33342. To demonstrate cell-density dependent
spheroid sizing, serial dilutions of h-PMSC (890–14,251
cells) in 40 μl of insert media were injected into the 3D
printed inserts and spheroid diameters measured using
NIH Image-J software. To measure the spheroid diam-
eter formation, 96 well plates were gently tapped against
a flat surface to encourage spheroids droplets to fall to
the bottom of the wells. This may also be accomplished
by pipetting air through the inserts or by centrifugation.
Results
The utility of 3D printed inserts as a 3D microtissue
generator was confirmed in a set of experiments
Fig. 1 Top view of (a) CAD 96 well insert with dimensions displayed and a hollow side view of (b) an individual insert with dimensions
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designed to monitor cellular spheroid formation. 3D
printed inserts were capable of maintaining 40 μl of cell-
loaded liquid suspensions in 96-well formats (see Figs. 1, 2).
Overall, the three different cell types evaluated with the 3D
printed insert system were effective in fabricating 3D spher-
oidal microtissues. Phase microscopy showed progressive
formation of spheroids over the course of 72 h (see Fig. 3).
At 10 min the U87 cells, showed clear individual cellular
dispersal in the liquid suspensions (see Fig. 3a). At 24 h, the
U87 cells began to aggregate into multiple cell clusters (see
Fig. 3b). At 48 h, the U87 cell clusters had merged into lar-
ger clusters (see Fig. 3c). By 72 h, the U87 cells displayed
large single spheroidal formations (see Fig. 3d). Similarly,
h-PMSC and h-ISMC formed single spheroids by 72 h (see
Figs. 4 and 5). Fluorescence staining showed viable live cell
clusters for each cell type examined (see Figs. 4 and 5).
Cell-density ‘tunability’ of spheroid size was achieved with
h-PMSC using different seeding concentrations. This
change created spheroids of increasing sized based on the
numbers of cells initially injected into the 3D printed in-
serts and were morphologically different from cellular
monolayers (see Fig. 5a and f ). Using an n = 12 for
each dilution set, each dilution series was significantly
different in size from each other group (***-p < 0.001).
Inserts seeded with 14,251 cells had a mean diameter
of 304.293 ± 20.8 μm (Mean ± standard deviation (SD))
(see Fig. 6a). Inserts seeded with 7,125 cells displayed
a mean diameter of 245.781 ± 23.236 μm (see Fig. 6b).
Inserts seeded with 1,781 cells displayed a mean
diameter of 187.307 ± 21.298 μm (see Fig. 6c). Inserts
seeded with 890 cells displayed a mean diameter of
149.83 ± 15.01 μm (see Fig. 6d). h-PMSCs seeded
above 1,781 cells appeared more symmetrical and
tight spheroid formations, while h-PMSCs seeded
under 890 cells formed less symmetrical and tightly
formed spheroids.
Fig. 2 Images of 96-well 3D printed inserts. a CAD model and (b-d) 3D printed inserts with liquid suspensions
Fig. 3 Phase microscopy images of U87 MG human glioblastoma cells at (a) 10 min, (b) 24 h, (c) 48 h, and (d) 72 h. Scale bar = 1000 μm
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Discussion
Advances in tissue engineering for both physiologic and
diseased tissue models have been achieved through 3D
printing of tissue scaffolds and direct bioprinting of cells
and tissue constructs, both of which have been previous
performed with spheroid and tissue-on-a-chip models
[15–25]. Although the use of 3D printing and bioprinting
has not been fully optimized, promising studies have dem-
onstrated its utility in fabricating implants in humans,
tissue-like constructs in animal models, and human-like
tissue models for drug screening [17–23]. 3D printed
ovary-like constructs have been implanted in mice with
surgically removed ovaries. The 3D printed ovary-like
constructs had a porous morphology, which accommo-
dated ovarian follicles in various stages of maturity. These
bioengineered ovary-like constructs allowed some mice to
become impregnated and produce offspring. Several in-
vestigators have used bioprinting to engineer tissue con-
structs for drug screening and disease modeling [25–27].
One group used bioprinting technology to assemble
Fig. 4 Images of Calcein-AM (green), ethidium homodimer 1 (red), and Hoechst 33342 fluorescence (blue) staining of (a and b) h-PMSC and (c)
h-ISMC at 72 h, Scale bar = 200 μm for each (a-c)
Fig. 5 Images of h-PMSC (a-d) stained with Calein AM at different cell densities at 72 h, scale bars = 200 μm. Images of Hoechst 33342 fluorescence
staining of h-PMSC (e) at 72 h at different focal planes, scale bar = 200 μm. Image of h-PMSC (f) monolayer on a flat polystyrene plate stained with
Calein AM, scale bar = 1000 μm
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human HepG2/C3A spheroids on a liver-on-a-chip plat-
form and demonstrated feasibility for this model for use
in drug toxicity screening [25].
This 3D printed microtissue insert approach can be
easily adapted for embryo culture, and in development
of tumor models and disease modeling. A potential ap-
plication of this model is in modeling tumor-endothelial
interactions in cancer invasion and metastasis. After
droplets containing spheroids have been transferred to
well bottoms, the spheroids contact, adhere, and eventu-
ally begin to migrate on the polystyrene surfaces. The
addition of a specific type of cell layer cell type on
underlying well bottom would permit evaluation of ad-
hesive and motile responses in tumor spheroids and
their responses to different drug treatments. These con-
siderations are now being explored and will be reported
in future studies.
Simple hanging drop concepts, hydrogels, and
biomaterials have been devised previously, but are not
designed for consumer grade 3D printers in 96-well
plate formats [28–30]. Hanging drop style 96-well plates
and ultra-low attachment systems exist on the market,
but may be challenging for groups to acquire due to the
cost. By comparison, the material cost for one PLA
96-well insert described in this study was $0.27 cents
($USD). This translates to $1.08 in material cost for 384
spheroid assays. The 3D printed PLA inserts can be
re-sterilized using gamma irradiation or as shown here,
using 70% ethanol, which further enhances cost effect-
iveness. Other high-temperature performing materials,
such as polycarbonates can also be used, which would
permit autoclaving. These types of customized cell cul-
ture inserts therefore have major advantages for research
groups with limited funding and access to consumer or
commercial grade 3D printers. 3D printing represents an
economical and practical tool for ad hoc, de novo, or
template-based creation of 3D printed constructs to aid
with tissue engineering, cell cultures, and other labora-
tory experiments [31].
This approach allowed rapid, high throughput and
reproducible production of cell spheroids for use in bio-
active screening assays. Through this method, a variety
of spheroids and co-cultures may be fabricated for
personalized medicine research. Higher cell numbers ap-
pear to encourage tighter cell-cell binding in spheroids
based on smoother profiles; this may be important in
models considering surface area, drug penetration and
nutrient/oxygen and waste exchange, all of which can be
‘tuned’ using applied cell counts. In this method, 40 μl
of cell-media was applied to each insert and cells
allowed to grow for 72 h. For testing drugs or bioactive
materials against spheroids, an additional 1–15 μl of a
desired bioactive-loaded solution can be loaded without
compromising drop stability. This system is not limited
to scaffold-free cultures, as other biomaterials and pre-
cious cargoes (e.g. micro and nanoparticles) may also be
added to the suspension cultures for tissue engineering
and drug carrier targeting studies. A limitation to the 3D
printed microtissue insert is the potential for suspension
dehydration overtime. However, 3–5 days is sufficient
for spheroid formation in an 100% humidity environ-
ment, which is critical for preventing suspension dehy-
dration. For long-term liquid suspension studies, inserts
may be modified to house a reservoir of media or liquid
to prevent evaporation. Such systems are currently being
designed and will be examined in the future.
Conclusions
The 3D printed microtissue inserts described in the
present study represents a cost-effective approach that
can be integrated in laboratories even with
consumer-grade 3D printers. A variety of tunable 3D
spheroid microtissues can be evaluated with this 3D
printed insert. Overall, it is suggested that these 3D
printed microtissue inserts have potential applications in
a variety of drug-delivery, disease modeling, and tissue
engineering systems.
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